Key result
Switching from glimepiride to mitiglinide/voglibose significantly decreased mean amplitude of glycemic excursion from 3.4 to 1.6 mmol/l and improved fasting and postprandial endothelial function.
Why the study?
Does switching from glimepiride to mitiglinide/voglibose improve glycemic variability and endothelial dysfunction in patients with type 2 diabetes?
Does switching from glimepiride to mitiglinide/voglibose improve glycemic variability and endothelial dysfunction in patients with type 2 diabetes?
Switching from a sulfonylurea to a mitiglinide/voglibose combination significantly improved glycemic variability and endothelial function in elderly patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
May improve glycemic variability and endothelial function in elderly T2D; hypothesis-generating and requires RCT confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2017) studied Type 2 diabetes (n=6). Mitiglinide/voglibose vs. Glimepiride (baseline) was evaluated on Mean amplitude of glycemic excursion (MAGE) (p=0.014). Switching from glimepiride to mitiglinide/voglibose significantly decreased mean amplitude of glycemic excursion from 3.4 to 1.6 mmol/l and improved fasting and postprandial endothelial function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: